Abstract
Type 2 diabetes is one of the leading causes of morbidity and mortality, consuming a significant proportion of public health spending. Oral hypoglycemic agents (OHAs) are the frontline treatment approaches after lifestyle changes. However, huge interindividual variation in response to OHAs results in unnecessary treatment failure. In addition to nongenetic factors, genetic factors are thought to contribute to much of such variability, highlighting the importance of the potential of pharmacogenetics to improve therapeutic outcome. Despite the presence of conflicting results, significant progress has been made in an effort to identify the genetic markers associated with pharmacokinetics, pharmacodynamics, and ultimately therapeutic response and/or adverse outcomes to OHAs. As such, this article presents a comprehensive review of current knowledge on pharmacogenetics of OHAs and provides insights into knowledge gaps and future directions.
Original language | English |
---|---|
Pages (from-to) | 17-29 |
Number of pages | 13 |
Journal | Pharmacogenomics and Personalized Medicine |
Volume | 9 |
DOIs | |
Publication status | Published - 6 Apr 2016 |
Keywords
- Oral hypoglycemic agents
- Pharmacodynamics
- Pharmacogenetics
- Pharmacokinetics
- Response
- Type 2 diabetes
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology